Irlandia - angielski - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

accord healthcare limited - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - bicalutamide - film-coated tablet - 150 milligram(s) - anti-androgens; bicalutamide

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - bicalutamide - film-coated tablet - 150 milligram(s) - anti-androgens; bicalutamide

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - bicalutamide - oral tablet - 50mg

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - bicalutamide - film-coated tablet - 50 milligram(s) - anti-androgens; bicalutamide

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

fair-med healthcare gmbh - bicalutamide - film-coated tablet - 150 milligram(s) - anti-androgens; bicalutamide

Australia - angielski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 400; lactose monohydrate; povidone; titanium dioxide; hypromellose; magnesium stearate; sodium starch glycollate type a - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 400; lactose monohydrate; povidone; titanium dioxide; hypromellose; magnesium stearate; sodium starch glycollate type a - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.